Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group (Q43898486)

27 November 2017

Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group (English)

1 reference

27 November 2017

1 reference

1 reference

0 references

placebo-controlled trial

1 reference

D W Cameron

1

1 reference

27 November 2017

M Heath-Chiozzi

2

1 reference

27 November 2017

S Danner

3

1 reference

27 November 2017

C Cohen

4

1 reference

27 November 2017

S Kravcik

5

1 reference

27 November 2017

C Maurath

6

1 reference

27 November 2017

E Sun

7

1 reference

27 November 2017

D Henry

8

1 reference

27 November 2017

R Rode

9

1 reference

27 November 2017

A Potthoff

10

1 reference

27 November 2017

J Leonard

11

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 February 1998

1 reference

27 November 2017

1 reference

27 November 2017

351

1 reference

27 November 2017

543-549

1 reference

27 November 2017

9102

1 reference

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

A controlled trial of zidovudine in primary human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinica

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

CD8+ lymphocyte responses to antiretroviral therapy of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2904161-5

7 January 2021

10.1016/S0140-6736(97)04161-5

Identifiers

DOI

1 reference

27 November 2017

1 reference